EW vs BSX

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus 11. 5% for Edwards Lifesciences Corporation (EW). Boston Scientific Corporation (BSX) offers the better valuation at 29. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Edwards Lifesciences Corporation (EW) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Boston Scientific Corporation (BSX) is the cheapest at 29.

2x versus Edwards Lifesciences Corporation at 45. 2x. On forward P/E, Boston Scientific Corporation is actually cheaper at 16. 7x.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -10. 2% for Edwards Lifesciences Corporation (EW). Over 10 years, the gap is even starker: BSX returned +155. 5% versus EW's +133. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Edwards Lifesciences Corporation's 0. 65β — meaning EW is approximately 90% more volatile than BSX relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 51% for Boston Scientific Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus 11. 5% for Edwards Lifesciences Corporation (EW). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -73. 7% for Edwards Lifesciences Corporation. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.

7% net margin versus 14. 4% for Boston Scientific Corporation — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus 19. 8% for BSX. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Boston Scientific Corporation (BSX) trades at 16.

7x forward P/E versus 27. 5x for Edwards Lifesciences Corporation — 10. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Boston Scientific Corporation (BSX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

34), +155. 5% 10Y return). Both have compounded well over 10 years (BSX: +155. 5%, EW: +133. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EW is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.